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Physicians and patients both have recognized a connection between asthma and respiratory infections since the disease was first described over two thousand years ago. The link has held throughout medical history until today; we recognize that about 80% of all asthma attacks can be associated with respiratory viral infections. We know a great deal more today than clinicians did in Hippocrates\' time about the mechanism of asthma pathogenesis and pathology but the picture is still not complete. The sequencing of the human genome ushered in a decade of intense research into the genetics of disease and we have made great advances, but a complex illness like asthma whose etiology involves individual differences in immune responses, as well as an array of environmental factors from microbial infection to tobacco smoke, has proven an exceptionally tough nut to crack.

It all started with the discovery of respiratory syncytial virus (RSV)\--specifically in the 1960s, when the connection between RSV infection and asthma became apparent. A depiction of the results from one of the earliest studies is illustrated in the accompanying figure ([Fig. 1](#fig1){ref-type="fig"} ), which elegantly shows the connection between infection and asthma. Those individuals who suffered a bout of RSV bronchiolitis clearly had a greater chance of having later asthma attacks. Over the years other viruses such as rhinovirus and metapneumovirus have been implicated in asthma.Fig. 1Connection between RSV bronchiolitis and asthma attack.(*Adapted from* Hyde, JS, and Saed, AM. Acute bronchiolitis and the asthmatic child. J Asthma Res 1966;4:137--54; with permission.)

While asthma can be controlled in most cases through existing drugs, there is still a need for developing new therapies based on a person's individual phenotype and this requires delving into the cellular and molecular details behind the results we obtain from clinical trials. No one questions that there is a connection between the etiology of asthma and the occurrence of respiratory infections, but a clear picture of the mechanisms involved and the variations that can occur in different individuals have yet to be attained. It is hoped that this compendium of recent advances in the field of asthma pathology and respiratory infections will help to define the problems, provide the reader with the current state of research, and stimulate fruitful discussions and new hypotheses to fuel future discoveries.

In the introductory article, Wong, Hellermann, and Mohapatra provide an overview of the common themes in the interaction between microbes and the immune system. They present and evaluate the evidence for an "infectious march" beginning in infancy, describe the various possible mechanisms of microbial influence in asthma, and discuss new and promising clinical practices for prevention and therapy. Recent data obtained by utilizing sensitive PCR detection methods have allowed more rigorous clinical testing of the causality hypothesis of virus infection leading to asthma, but the evidence is still equivocal. Determining the "asthmagenic" potential of the many different types of bacteria and viruses that can colonize the respiratory tract is a daunting challenge. The important clinical trials are reviewed and various exceptions and inconsistencies in the results are discussed in light of new information on the inflammatory immune responses to microbial attack. The existing guidelines for subject inclusion/exclusion, types of outcome chosen, and data analysis are examined in hopes of providing some standardization. Despite past failures in vaccination and disappointing results of some clinical trials, the new strategies for prophylaxis including RNA interference, targeted microbicides, and inhibition of viral proteins offer a large dose of hope to a world suffering from an increasing incidence of asthma and a huge burden of health care cost and loss of quality of life.

The discussion continues with an article by Drs Kloepfer and Gern on the allergic asthmatic and their particular responses to viral respiratory infections. Allergen exposure is a common cause of asthma attacks, and when accompanied by a viral respiratory infection, the symptoms can be much more severe. The majority of asthma exacerbations have been found to also involve viral infections and much research has been done to define and understand the synergy between these two triggers of asthma exacerbation. An effective host antiviral response requires interferon production and expression of interferon response genes, and individual differences in the virus-neutralizing capability may occur under conditions of allergen exposure to increase the risk of an exacerbation and the severity of the attack. The combination of allergen sensitivity and exposure and virus infection, especially with rhinovirus, is frequently seen in children hospitalized for exacerbation. Recent studies using more sensitive detection methods have shown that rhinovirus can penetrate to the lower airways where it could interact with inflammation caused by allergen exposure. Underproduction of interferons or individual polarization toward a T helper cell 2-like cytokine environment could fuel the synergy seen in virus/allergen cases.

Dr Miller provides some highly interesting new information about the recently discovered species of human rhinovirus known as HRVC. More than 100 serotypes of the common cold virus have been identified over the years, but with the advent of more sensitive detection methods such as quantitative reverse-transcriptase PCR, the role of HRV in human diseases such as asthma has proven to be much greater than previously thought. Evidence is accumulating that shows HRV is more frequently associated with exacerbations than is RSV and that HRV may be linked to inception of asthma in children. HRVC is a genetically distinct species that is difficult to culture. Quantitative PCR methods, however, allow positive identification in sputum or nasal swabs. Some studies using these PCR methods have shown HVRC to be associated with a large proportion of hospitalizations for upper and lower respiratory illness, but other studies have shown no difference between HRVA, -B, and -C. As with nearly everything in asthma pathology, the answers are not simple or clear-cut and more work is definitely needed. Whether or not HRVC turns out to be more "asthmagenic" than other viruses remains to be determined.

Continuing with the theme of viral association in asthma inception, Drs Jackson and Lemanske explore the knotty question of whether viral bronchiolitis in infancy leads to asthma in childhood or if cellular and molecular conditions exist that predispose an individual to suffer both severe bronchiolitis and later asthma. Needless to say, the jury is still out on this matter, but are we closer to an unequivocal answer? The problem as usual lies in translating the in vitro and animal results to human trials. This article discusses in detail the clinical evidence related to the various hypotheses. All children are infected with respiratory viruses, but only some of the children who suffer viral bronchiolitis go on to develop wheezing and asthma that persist into adulthood. It may be informative to investigate the proteomics of those who "outgrow" their asthma with a view to teasing out the differences that preserve them from disease. More clinical studies of specific age groups, with long-term follow-up and tracking of molecular markers of inflammation and immunity, are needed to finally put this issue to rest.

Drs Westerly and Peebles survey the literature and offer up a cogent discussion about the role of RSV infection in the pathogenesis and progression of asthma in adults. The immune responses of asthmatics are different from those of nonasthmatics and we need to understand how this relates to respiratory virus susceptibility, severity of infection, and risk of exacerbation. One important consideration that needs to be addressed in RSV studies is that of seasonality, since unlike HRV, RSV has clear peaks of infection in the fall and winter. Here again, the authors emphasize the importance of using the sensitive and specific quantitative PCR method for virus detection. The elderly person is commonly at greater risk of pneumonia from respiratory virus infections than younger adults are and RSV is estimated to cause about 10,000 deaths per year in the over-65 age group. The immune system is not very good at curbing RSV infections and the reason for this seems to lie in RSV's ability to block the host cell's antiviral interferon defense system. Within hours after infecting a mucosal epithelial cell, the earliest RSV proteins, nonstructural protein-1 (NS1) and -2 (NS2), have been synthesized and are going to work to block expression of interferon and consequently the interferon-responsive genes. The viral proteins also prevent apoptosis of virally infected cells, allowing replication to proceed and titers to rise so that additional cells can be infected. The authors provide a detailed review of the changes and differences in cytokine levels, inflammatory mediators, and cellular profiles relating to RSV infection and exacerbation in asthmatics versus nonasthmatics.

The literature about the effects of a variety of less common respiratory viruses on asthma along with some newly identified virus candidates is reviewed and discussed by Dr McErlean, Ms Greiman, and Drs Favoreto and Avila. The viruses addressed include human metapneumovirus (HMPV; described pre-SARS), the human rhinovirus species C (HRVC), human coronaviruses (HCoVs) -NL63 and -HKU1, human bocavirus (HBoV), and the KI and WU polyoma-viruses (KIPyV and WUPyV). Some of the interesting questions reviewed by the authors include whether one virus such as HRV can suppress the replication of another such as influenzavirus, how asthma phenotype might affect colonization by specific viruses, and how differences in virus serotypes alter the risk of exacerbation or the severity of the reaction. The application of highly sensitive tests such as quantitative PCR for virus detection has demonstrated that coinfection with more than one virus is common, yet it is intriguing that this does not appear to increase the severity of an associated exacerbation. The enhanced detection capability has resulted in the detection of some newly identified viruses ("NIVs") among which were two types of polyoma virus discovered in 2007 associated with acute respiratory infections, bronchiolitis, and pneumonia. Whether these NIVs play any part in asthma pathogenesis or exacerbation has not yet been determined but they are especially interesting because there is evidence that they can exist in a latent form in cells and be reactivated under certain conditions.

Dr Rosenthal discusses the pros and cons of using mice and rats as models to study human asthma. The anatomy and physiology of the rodent respiratory system and their immune responses are different from those of humans. Other animal asthma models include guinea pigs, cotton rats, sheep, and nonhuman primates. The use of inbred rodent strains decreases the variability in results due to genotype. What constitutes an "ideal" rodent model? (1) The capability of studying the effects of infections and allergen sensitivity on asthma development, (2) the ability to test host genetic factors, (3) being able to look at the relationship between development of the immune system and pulmonary physiology, (4) the means to address changes in the airways due to chronic inflammation, and (5) changes due to immune senescence. The problems with limited replication of human viruses in rodents is partially solved by using rodent viruses such as mengovirus and sendai virus but these viruses may behave differently from their human counterparts. The use of gene-knockout strains of mice provides data about involvement of specific ligands, receptors, and enzymes in response to viral infection and development of asthma, and the use of conditional and inducible knockouts has further refined this method. Rodent models are also amenable to dose-response studies with environmental challenges such as tobacco smoke or diesel exhaust particles that would be unethical to do on humans. The short lifespan of the rodent makes it especially useful for aging and developmental studies.

The influence of specific bacterial infections on the pathogenesis of asthma is reviewed and evaluated by Dr Korppi. Bacteria such as *Mycoplasma pneumoniae* and *Chlamydophila pneumoniae* are associated with asthma exacerbations but antibiotics seem to be of little use in preventing them. Despite the hygiene hypothesis, the results confirm that early-life colonization with bacterial pathogens is not beneficial. However, the lower airways appear to have their own normal microbiota that is altered in asthmatics. Changes in the normal flora in childhood may affect asthma susceptibility. In fact, *C pneumoniae* may cause an occult chronic infection and inflammation in the airways and participate in the inception or pathogenesis of asthma. Increased sensitivity of detection methods may reveal infection where none was seen before. The new techniques have also shown us that the normal microbiota of humans is much more varied than earlier believed.

Drs Metz and Kraft expand upon the problems surrounding the effects of atypical infections with *M pneumoniae* and *C pneumoniae* on asthma susceptibility and exacerbation. There is emerging evidence to suggest that atypical bacterial infections are positively correlated with asthma exacerbations, chronic asthma, and severity of disease. Significant limitations exist in evaluating atypical bacterial infections in the lung due to difficulties with sampling and detection. The mechanisms of infection and the host responses as they relate to asthma inception and pathology are presented, followed by clinical evidence for involvement of atypical bacterial infection in exacerbations. The data support the idea that infection with atypical bacteria is associated with a worsening of asthma symptoms, especially during exacerbation, and with the development of chronic asthma. The bacterial attack on respiratory cells, cytokine involvement, oxidative stress, and epithelial cell denudation are all factors that are evaluated for their potential role in worsening asthma symptoms. Each bacterial type possesses unique mechanisms of action and the authors attempt to relate this to the observed effects on asthma. Antibiotics such as clarithromycin and roxithromycin have been tested with a view to reducing asthma exacerbations through reductions in bacterial colonization but results have been mixed.

In conclusion, the role of infection in asthma inception and pathogenesis has become clearer in the past decade but clinicians and basic scientists still have a way to go before all the details are worked out. The greatest hope for the future lies in the accessibility of a wonderful array of new tools from quantitative real-time PCR to 4D confocal microscopy and new types of microarrays. The tools are only as good as the minds that wield them, however, and it is hoped that this review of the asthma literature in relation to microbial attack will serve to stimulate thought that translates into action at the bench and new therapies in the clinic.
